CompletedInterventionalPhase 3Updated Aug 27, 2018
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine | NCT01728025 | Trialant
Unknown statusInterventionalPhase 2Updated Mar 26, 2015
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
ClinicalTrials.gov ID
NCT01728025
Lead Sponsor
Tel-Aviv Sourasky Medical CenterOTHER_GOV
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 2
Enrollment
10Estimated
Last Update Posted
Mar 26, 2015Estimated
Start Date
Oct 2012
Primary Completion Date
Nov 2017Estimated
Completion Date
Nov 2017Estimated
Brief Summary
The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.
Long QT Syndrome Type 3
Ranolazine
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene
Corrected QT interval > 460 msec
Exclusion Criteria:
Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors)